Skip to content

Contact Us
Careers

Contact Us
Careers

Company

TVAX Immunotherapy^®

TVI-Brain-1

Pipeline

Patient Resources

News

About TVAX Biomedical
Management
Board of Directors

About TVAX Biomedical
Management
Board of Directors

Manufacturing
Support References

Manufacturing
Support References

Additional Programs

Additional Programs

Author name: Tvaxbio2

TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study

Tvaxbio2 / October 18, 2022

OLATHE, Kan., Oct. 18, 2022 — TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study […]

TVAX Biomedical Receives Fast Track Designation from the FDA

Tvaxbio2 / April 30, 2020

Olathe, KS, April 30, 2020 – TVAX Biomedical today announced receipt of Fast Track Designation from the US Food and

TVAX Biomedical Names Wayne Carter as President and CEO

Tvaxbio2 / March 11, 2019

Olathe, KS, March 11, 2019 – TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for

Revolutionizing Cancer Care, One Patient at a Time

About
Patient Resources
News
Pipeline

THE TVAX IMMUNOTHERAPY® PLATFORM
TVI-BRAIN-1
Careers
Contact Us

PRIVACY POLICY | TERMS OF USE

© 2024 - 2026 TVAX Biomedical, Inc. All Rights Reserved.

Scroll to Top